Inactivation of viruses in platelet and plasma products using a riboflavin-and-UV-based photochemical treatment
BACKGROUND Multilayered blood safety programs reduce the risk of transfusion‐transmitted diseases; however, there remains a risk of window period transmission of screened viruses and transmission of unscreened and emerging viruses from asymptomatic donors. To reduce this risk, a riboflavin‐and‐UV‐li...
Gespeichert in:
| Veröffentlicht in: | Transfusion (Philadelphia, Pa.) Pa.), 2015-07, Vol.55 (7), p.1736-1744 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1744 |
|---|---|
| container_issue | 7 |
| container_start_page | 1736 |
| container_title | Transfusion (Philadelphia, Pa.) |
| container_volume | 55 |
| creator | Keil, Shawn D. Bengrine, Abderrahmane Bowen, Richard Marschner, Susanne Hovenga, Nick Rouse, Lindsay Gilmour, Denise Duverlie, Gilles Goodrich, Raymond P. |
| description | BACKGROUND
Multilayered blood safety programs reduce the risk of transfusion‐transmitted diseases; however, there remains a risk of window period transmission of screened viruses and transmission of unscreened and emerging viruses from asymptomatic donors. To reduce this risk, a riboflavin‐and‐UV‐light–based pathogen reduction process was evaluated against eight viral agents.
STUDY DESIGN AND METHODS
Riboflavin and UV light was evaluated against the following eight viral agents: encephalomyocarditis virus (EMC), hepatitis A virus (HAV), hepatitis C virus (HCV), influenza A (FLUAV), La Crosse virus (LACV), pseudorabies virus (PRV), sindbis virus (SINV), and vesicular stomatitis virus (VSV). Before treatment, a sample was removed to determine the product's initial viral load. After treatment the product's viral load was reevaluated and the log reduction was calculated.
RESULTS
Virus reduction after treatment with riboflavin and UV light is equivalent in platelet (PLT) and plasma units, as demonstrated by a 3.2‐log reduction of EMC in plasma, PLTs, and PLT additive solution containing 35% plasma. Additionally, the following viral reductions values were observed: HAV 1.8 log, HCV at least 4.1 log, FLUAV at least 5.0 log, LACV at least 3.5 log, PRV 2.5 log, SINV 3.2 log, and VSV at least 6.3 log.
CONCLUSIONS
The results observed in this study suggest that treating PLT and plasma products with a riboflavin‐and‐UV‐light–based pathogen reduction process could potentially eliminate window period transmission of screened viruses and greatly reduce the risk of transfusion transmission of unscreened viruses. |
| doi_str_mv | 10.1111/trf.13030 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1697214388</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3742713311</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4610-e53c9af587ff953bda208b07301bc6ca38263e7ad18e96a30a7b7c8147c563fb3</originalsourceid><addsrcrecordid>eNp10cFu1DAQBmALgei2cOAFkCUu9JDWjpM4OaKK3a1UFVS1cLQmzpi6JPbWdhb69njZtgckfBlZ-ubXaIaQd5yd8PxOUzAnXDDBXpAFr4Usyq6rX5IFYxUvOBflATmM8Y4xVnaMvyYHZS0Fb5hcEH_uQCe7hWS9o97QrQ1zxEito5sREo6YKLhh94kT0E3ww6xTpHO07gcFGmzvzQhb64rMiptvRQ8Rs7_1yetbnKyGkaaAkCZ06Q15ZWCM-PaxHpGb5efrs3Vx8WV1fvbpotBVw1mBtdAdmLqVxnS16AcoWdszKRjvdaNBtGUjUMLAW-waEAxkL3XLK6nrRpheHJGP-9w88P2MManJRo3jCA79HBVvOlnySrRtph_-oXd-Di5Pt1N5S7u1ZXW8Vzr4GAMatQl2gvCgOFO7K6h8BfX3Ctm-f0yc-wmHZ_m09gxO9-CXHfHh_0nq-mr5FFnsO2xM-Pu5A8JP1Ugha_X9cqWq9eV6ubz6qlbiDxDQoO4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1696070029</pqid></control><display><type>article</type><title>Inactivation of viruses in platelet and plasma products using a riboflavin-and-UV-based photochemical treatment</title><source>MEDLINE</source><source>Wiley Online Library All Journals</source><creator>Keil, Shawn D. ; Bengrine, Abderrahmane ; Bowen, Richard ; Marschner, Susanne ; Hovenga, Nick ; Rouse, Lindsay ; Gilmour, Denise ; Duverlie, Gilles ; Goodrich, Raymond P.</creator><creatorcontrib>Keil, Shawn D. ; Bengrine, Abderrahmane ; Bowen, Richard ; Marschner, Susanne ; Hovenga, Nick ; Rouse, Lindsay ; Gilmour, Denise ; Duverlie, Gilles ; Goodrich, Raymond P.</creatorcontrib><description>BACKGROUND
Multilayered blood safety programs reduce the risk of transfusion‐transmitted diseases; however, there remains a risk of window period transmission of screened viruses and transmission of unscreened and emerging viruses from asymptomatic donors. To reduce this risk, a riboflavin‐and‐UV‐light–based pathogen reduction process was evaluated against eight viral agents.
STUDY DESIGN AND METHODS
Riboflavin and UV light was evaluated against the following eight viral agents: encephalomyocarditis virus (EMC), hepatitis A virus (HAV), hepatitis C virus (HCV), influenza A (FLUAV), La Crosse virus (LACV), pseudorabies virus (PRV), sindbis virus (SINV), and vesicular stomatitis virus (VSV). Before treatment, a sample was removed to determine the product's initial viral load. After treatment the product's viral load was reevaluated and the log reduction was calculated.
RESULTS
Virus reduction after treatment with riboflavin and UV light is equivalent in platelet (PLT) and plasma units, as demonstrated by a 3.2‐log reduction of EMC in plasma, PLTs, and PLT additive solution containing 35% plasma. Additionally, the following viral reductions values were observed: HAV 1.8 log, HCV at least 4.1 log, FLUAV at least 5.0 log, LACV at least 3.5 log, PRV 2.5 log, SINV 3.2 log, and VSV at least 6.3 log.
CONCLUSIONS
The results observed in this study suggest that treating PLT and plasma products with a riboflavin‐and‐UV‐light–based pathogen reduction process could potentially eliminate window period transmission of screened viruses and greatly reduce the risk of transfusion transmission of unscreened viruses.</description><identifier>ISSN: 0041-1132</identifier><identifier>EISSN: 1537-2995</identifier><identifier>DOI: 10.1111/trf.13030</identifier><identifier>PMID: 25731607</identifier><identifier>CODEN: TRANAT</identifier><language>eng</language><publisher>United States: Blackwell Publishing Ltd</publisher><subject>Blood Platelets - virology ; HIV ; Human immunodeficiency virus ; Humans ; Photosensitizing Agents - pharmacology ; Plasma ; Plasma - virology ; Riboflavin - pharmacology ; RNA Viruses ; Ultraviolet Rays ; Viral Load ; Virus Inactivation - drug effects ; Virus Inactivation - radiation effects ; Viruses ; Vitamin B</subject><ispartof>Transfusion (Philadelphia, Pa.), 2015-07, Vol.55 (7), p.1736-1744</ispartof><rights>2015 AABB</rights><rights>2015 AABB.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4610-e53c9af587ff953bda208b07301bc6ca38263e7ad18e96a30a7b7c8147c563fb3</citedby><cites>FETCH-LOGICAL-c4610-e53c9af587ff953bda208b07301bc6ca38263e7ad18e96a30a7b7c8147c563fb3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Ftrf.13030$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Ftrf.13030$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1416,27923,27924,45573,45574</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25731607$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Keil, Shawn D.</creatorcontrib><creatorcontrib>Bengrine, Abderrahmane</creatorcontrib><creatorcontrib>Bowen, Richard</creatorcontrib><creatorcontrib>Marschner, Susanne</creatorcontrib><creatorcontrib>Hovenga, Nick</creatorcontrib><creatorcontrib>Rouse, Lindsay</creatorcontrib><creatorcontrib>Gilmour, Denise</creatorcontrib><creatorcontrib>Duverlie, Gilles</creatorcontrib><creatorcontrib>Goodrich, Raymond P.</creatorcontrib><title>Inactivation of viruses in platelet and plasma products using a riboflavin-and-UV-based photochemical treatment</title><title>Transfusion (Philadelphia, Pa.)</title><addtitle>Transfusion</addtitle><description>BACKGROUND
Multilayered blood safety programs reduce the risk of transfusion‐transmitted diseases; however, there remains a risk of window period transmission of screened viruses and transmission of unscreened and emerging viruses from asymptomatic donors. To reduce this risk, a riboflavin‐and‐UV‐light–based pathogen reduction process was evaluated against eight viral agents.
STUDY DESIGN AND METHODS
Riboflavin and UV light was evaluated against the following eight viral agents: encephalomyocarditis virus (EMC), hepatitis A virus (HAV), hepatitis C virus (HCV), influenza A (FLUAV), La Crosse virus (LACV), pseudorabies virus (PRV), sindbis virus (SINV), and vesicular stomatitis virus (VSV). Before treatment, a sample was removed to determine the product's initial viral load. After treatment the product's viral load was reevaluated and the log reduction was calculated.
RESULTS
Virus reduction after treatment with riboflavin and UV light is equivalent in platelet (PLT) and plasma units, as demonstrated by a 3.2‐log reduction of EMC in plasma, PLTs, and PLT additive solution containing 35% plasma. Additionally, the following viral reductions values were observed: HAV 1.8 log, HCV at least 4.1 log, FLUAV at least 5.0 log, LACV at least 3.5 log, PRV 2.5 log, SINV 3.2 log, and VSV at least 6.3 log.
CONCLUSIONS
The results observed in this study suggest that treating PLT and plasma products with a riboflavin‐and‐UV‐light–based pathogen reduction process could potentially eliminate window period transmission of screened viruses and greatly reduce the risk of transfusion transmission of unscreened viruses.</description><subject>Blood Platelets - virology</subject><subject>HIV</subject><subject>Human immunodeficiency virus</subject><subject>Humans</subject><subject>Photosensitizing Agents - pharmacology</subject><subject>Plasma</subject><subject>Plasma - virology</subject><subject>Riboflavin - pharmacology</subject><subject>RNA Viruses</subject><subject>Ultraviolet Rays</subject><subject>Viral Load</subject><subject>Virus Inactivation - drug effects</subject><subject>Virus Inactivation - radiation effects</subject><subject>Viruses</subject><subject>Vitamin B</subject><issn>0041-1132</issn><issn>1537-2995</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp10cFu1DAQBmALgei2cOAFkCUu9JDWjpM4OaKK3a1UFVS1cLQmzpi6JPbWdhb69njZtgckfBlZ-ubXaIaQd5yd8PxOUzAnXDDBXpAFr4Usyq6rX5IFYxUvOBflATmM8Y4xVnaMvyYHZS0Fb5hcEH_uQCe7hWS9o97QrQ1zxEito5sREo6YKLhh94kT0E3ww6xTpHO07gcFGmzvzQhb64rMiptvRQ8Rs7_1yetbnKyGkaaAkCZ06Q15ZWCM-PaxHpGb5efrs3Vx8WV1fvbpotBVw1mBtdAdmLqVxnS16AcoWdszKRjvdaNBtGUjUMLAW-waEAxkL3XLK6nrRpheHJGP-9w88P2MManJRo3jCA79HBVvOlnySrRtph_-oXd-Di5Pt1N5S7u1ZXW8Vzr4GAMatQl2gvCgOFO7K6h8BfX3Ctm-f0yc-wmHZ_m09gxO9-CXHfHh_0nq-mr5FFnsO2xM-Pu5A8JP1Ugha_X9cqWq9eV6ubz6qlbiDxDQoO4</recordid><startdate>201507</startdate><enddate>201507</enddate><creator>Keil, Shawn D.</creator><creator>Bengrine, Abderrahmane</creator><creator>Bowen, Richard</creator><creator>Marschner, Susanne</creator><creator>Hovenga, Nick</creator><creator>Rouse, Lindsay</creator><creator>Gilmour, Denise</creator><creator>Duverlie, Gilles</creator><creator>Goodrich, Raymond P.</creator><general>Blackwell Publishing Ltd</general><general>Wiley Subscription Services, Inc</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7U9</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>201507</creationdate><title>Inactivation of viruses in platelet and plasma products using a riboflavin-and-UV-based photochemical treatment</title><author>Keil, Shawn D. ; Bengrine, Abderrahmane ; Bowen, Richard ; Marschner, Susanne ; Hovenga, Nick ; Rouse, Lindsay ; Gilmour, Denise ; Duverlie, Gilles ; Goodrich, Raymond P.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4610-e53c9af587ff953bda208b07301bc6ca38263e7ad18e96a30a7b7c8147c563fb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Blood Platelets - virology</topic><topic>HIV</topic><topic>Human immunodeficiency virus</topic><topic>Humans</topic><topic>Photosensitizing Agents - pharmacology</topic><topic>Plasma</topic><topic>Plasma - virology</topic><topic>Riboflavin - pharmacology</topic><topic>RNA Viruses</topic><topic>Ultraviolet Rays</topic><topic>Viral Load</topic><topic>Virus Inactivation - drug effects</topic><topic>Virus Inactivation - radiation effects</topic><topic>Viruses</topic><topic>Vitamin B</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Keil, Shawn D.</creatorcontrib><creatorcontrib>Bengrine, Abderrahmane</creatorcontrib><creatorcontrib>Bowen, Richard</creatorcontrib><creatorcontrib>Marschner, Susanne</creatorcontrib><creatorcontrib>Hovenga, Nick</creatorcontrib><creatorcontrib>Rouse, Lindsay</creatorcontrib><creatorcontrib>Gilmour, Denise</creatorcontrib><creatorcontrib>Duverlie, Gilles</creatorcontrib><creatorcontrib>Goodrich, Raymond P.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Transfusion (Philadelphia, Pa.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Keil, Shawn D.</au><au>Bengrine, Abderrahmane</au><au>Bowen, Richard</au><au>Marschner, Susanne</au><au>Hovenga, Nick</au><au>Rouse, Lindsay</au><au>Gilmour, Denise</au><au>Duverlie, Gilles</au><au>Goodrich, Raymond P.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Inactivation of viruses in platelet and plasma products using a riboflavin-and-UV-based photochemical treatment</atitle><jtitle>Transfusion (Philadelphia, Pa.)</jtitle><addtitle>Transfusion</addtitle><date>2015-07</date><risdate>2015</risdate><volume>55</volume><issue>7</issue><spage>1736</spage><epage>1744</epage><pages>1736-1744</pages><issn>0041-1132</issn><eissn>1537-2995</eissn><coden>TRANAT</coden><abstract>BACKGROUND
Multilayered blood safety programs reduce the risk of transfusion‐transmitted diseases; however, there remains a risk of window period transmission of screened viruses and transmission of unscreened and emerging viruses from asymptomatic donors. To reduce this risk, a riboflavin‐and‐UV‐light–based pathogen reduction process was evaluated against eight viral agents.
STUDY DESIGN AND METHODS
Riboflavin and UV light was evaluated against the following eight viral agents: encephalomyocarditis virus (EMC), hepatitis A virus (HAV), hepatitis C virus (HCV), influenza A (FLUAV), La Crosse virus (LACV), pseudorabies virus (PRV), sindbis virus (SINV), and vesicular stomatitis virus (VSV). Before treatment, a sample was removed to determine the product's initial viral load. After treatment the product's viral load was reevaluated and the log reduction was calculated.
RESULTS
Virus reduction after treatment with riboflavin and UV light is equivalent in platelet (PLT) and plasma units, as demonstrated by a 3.2‐log reduction of EMC in plasma, PLTs, and PLT additive solution containing 35% plasma. Additionally, the following viral reductions values were observed: HAV 1.8 log, HCV at least 4.1 log, FLUAV at least 5.0 log, LACV at least 3.5 log, PRV 2.5 log, SINV 3.2 log, and VSV at least 6.3 log.
CONCLUSIONS
The results observed in this study suggest that treating PLT and plasma products with a riboflavin‐and‐UV‐light–based pathogen reduction process could potentially eliminate window period transmission of screened viruses and greatly reduce the risk of transfusion transmission of unscreened viruses.</abstract><cop>United States</cop><pub>Blackwell Publishing Ltd</pub><pmid>25731607</pmid><doi>10.1111/trf.13030</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0041-1132 |
| ispartof | Transfusion (Philadelphia, Pa.), 2015-07, Vol.55 (7), p.1736-1744 |
| issn | 0041-1132 1537-2995 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1697214388 |
| source | MEDLINE; Wiley Online Library All Journals |
| subjects | Blood Platelets - virology HIV Human immunodeficiency virus Humans Photosensitizing Agents - pharmacology Plasma Plasma - virology Riboflavin - pharmacology RNA Viruses Ultraviolet Rays Viral Load Virus Inactivation - drug effects Virus Inactivation - radiation effects Viruses Vitamin B |
| title | Inactivation of viruses in platelet and plasma products using a riboflavin-and-UV-based photochemical treatment |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T05%3A19%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Inactivation%20of%20viruses%20in%20platelet%20and%20plasma%20products%20using%20a%20riboflavin-and-UV-based%20photochemical%20treatment&rft.jtitle=Transfusion%20(Philadelphia,%20Pa.)&rft.au=Keil,%20Shawn%20D.&rft.date=2015-07&rft.volume=55&rft.issue=7&rft.spage=1736&rft.epage=1744&rft.pages=1736-1744&rft.issn=0041-1132&rft.eissn=1537-2995&rft.coden=TRANAT&rft_id=info:doi/10.1111/trf.13030&rft_dat=%3Cproquest_cross%3E3742713311%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1696070029&rft_id=info:pmid/25731607&rfr_iscdi=true |